Inhibition of neuroblastoma cell growth by TREX1-mutated human lymphocytes

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1689-1694

  Pulliero, A ^a   Marengo, B ^b   Domenicotti, C ^a   Longobardi, M G ^a   Fazzi, E ^c   Orcesi, S ^d   Bianchi, M ^e   Balottin, U ^d   Izzotti, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Aicardi Gouti res syndrome; Angiogenesis; Interferon; Neuroblastoma; TREX1 mutated lymphocytes

Indexed keywords

ALPHA INTERFERON;

AICARDI GOUTIERES SYNDROME; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MALE; MOLECULAR RECOGNITION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREX1 GENE; TUMOR GENE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

CATHEPSIN D; CELL LINE; CELL PROLIFERATION; EXODEOXYRIBONUCLEASES; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PHOSPHOPROTEINS;

EID: 84858213828     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1696     Document Type: Article

References (31)

1. Knutson KL and Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54: 721-728, 2005. (Pubitemid 40977140)
2. Zwirner NW, Croci DO, Domaica CI and Rabinovich GA: Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr Pharm Des 16: 255-267, 2010.
3. cip1/waf1 degradation and cell proliferation in HeLa cells. Cell Cycle 9: 131-139, 2010.
4. Burchert A, Müller MC, Kostrewa P, et al: Sustained molecular response with interferon α maintenance after induction therapy with imatinib plus interferon α in patients with chronic myeloid leukemia. J Clin Oncol 28: 1429-1435, 2010.
5. Panetta JD and Gilani N: Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther 15: 597-602, 2009.
6. Lanzi G, D'Arrigo S, Drumbl G, Uggetti C and Fazzi E: Aicardi-Goutières syndrome: differential diagnosis and aetiopathogenesis. Funct Neurol 18: 71-75, 2003. (Pubitemid 36903300)
7. Izzotti A, Pulliero A, Orcesi S, et al: Interferon-related transcriptome alterations in the cerebrospinal fluid cells of Aicardi-Goutières patients. Brain Pathol 19: 650-660, 2009.
8. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, et al: Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41: 829-832, 2009.
9. Rice G, Newman WG, Dean J, et al: Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome. Am J Hum Genet 80: 811-815, 2007. (Pubitemid 46564418)
10. Izzotti A, Fazzi E, Orcesi S, et al: Brain damage as detected by cDNA-microarray in the spinal fluid of patients with Aicardi-Goutières syndrome. Neurology 71: 610-612, 2008.
11. Ling PD and Huls HM: Isolation and immortalization of lymphocytes. Curr Protoc Mol Biol 28: Unit 28.2, 2005.
12. Ferrari N, Pfeffer U, Dell'Eva R, et al: The transforming growth factor-β family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res 11: 4610-4619, 2005. (Pubitemid 40825652)
13. Voigt A and Zintl F: Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med Pediatr Oncol 40: 205-213, 2003. (Pubitemid 36222824)
14. Abushahba W, Balan M, Castaneda I, et al: Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59: 1059-1071, 2010.
15. Zhu Y, Tibensky I, Schmidt J, et al: Interferon-alpha in combin- ation with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31: 28-33, 2008. (Pubitemid 351619401)
16. Kubota T, Taiyoh H, Matsumura A, et al: Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation. Int J Cancer 125: 2879-2886, 2009.
17. Murdoch C, Tazzyman S, Webster S and Lewis CE: Expression of Tie-2 by human monocytes and their responses to angio-poietin-2. J Immunol 178: 7405-7411, 2007. (Pubitemid 46847468)
18. Anderson MJ, Shafer-Weaver K, Greenberg NM and Hurwitz AA: Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178: 1268-1276, 2007. (Pubitemid 46154596)
19. Nakanishi H: Neuronal and microglial cathepsins in aging and age-related diseases. Aging Res Rev 2: 367-381, 2003.
20. Beaujouin M and Liaudet-Coopman E: Cathepsin D overexpressed by cancer cells can enhance apoptosis-dependent chemo-sensitivity independently of its catalytic activity. Adv Exp Med Biol 617: 453-461, 2008.
21. Zheng X, Chu F, Mirkin BL, et al: Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta 1783: 2294-2300, 2008.
22. Liaudet-Coopman E, Beaujouin M, Derocq D, et al: Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 237: 167-179, 2006. (Pubitemid 43777078)
23. Qiao L, Hamamichi S, Caldwell KA, et al: Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 21: 1-17, 2008.
24. Yang YG, Lindahl T and Barnes DE: Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131: 836-838, 2007.
25. Ishii KJ and Akira S: Innate immune recognition of nucleic acids: beyond toll-like receptors. Int J Cancer 117: 517-523, 2005. (Pubitemid 41504538)
26. Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T and Perrino FW: The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. Biol Chem 283: 31649-31656, 2008.
27. Lindahl T, Barnes DE, Yang YG and Robins P: Biochemical properties of mammalian TREX1 and its association with DNA replication and inherited inflammatory disease. Arthritis Rheum 37: 535-538, 2009.
28. Wagner H: Endogenous TLR ligands and autoimmunity. Adv Immunol 91: 159-173, 2006.
29. Stetson DB, Ko JS, Heidmann T and Medzhitov R: Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587-598, 2008.
30. Ramantani G, Kohlhase J, Hertzberg C, et al: Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum 62: 1469-1477, 2010.
31. Orcesi S, La Piana R and Fazzi E: Aicardi-Goutières syndrome. Br Med Bull 89: 183-201, 2009.